Sensitization to TLR7 Agonist in IFN-beta-preactivated Dendritic Cells
Overview
Authors
Affiliations
TLRs interact with a growing list of pathogen-derived products and these interactions drive the activation of innate and adaptive immune responses. Dendritic cells (DC) play a key role in these events expressing a heterogeneous repertoire of TLRs. We have previously demonstrated the production of type I IFNs in DC following bacterial infections and TLR triggering. In this study, we sought to characterize the transcriptome specifically induced in human DC by IFN-beta production stimulated upon LPS treatment. To this aim, by using cDNA microarrays, we compared the transcriptome of DC following LPS treatment in the absence or presence of neutralizing anti-type I IFN Abs. Interestingly, we found that the expression of TLR7 was induced during LPS-induced maturation of DC in a type I IFN-dependent manner. The induction of TLR7 in maturing DC was mainly a consequence of the transcriptional activity of IRF-1, whose binding site was located within TLR7 promoter. Moreover, we also demonstrated that "priming" of immature DC, that usually express TLR8 but not TLR7, with exogenous IFN-beta induced a functionally active TLR7. In fact, treatment with the TLR7-specific ligand 3M-001 up-regulated the expression of CD83, CD86, and CD38 in IFN-beta-primed DC but not in immature DC. Therefore, a robust enhancement in proinflammatory as well as regulatory cytokines was observed. These data suggest that TLR4-mediated type I IFN release activates specific transcription programs in DC amplifying the expression of pathogen sensors to correctly and combinatorially respond to a bacterial as well as viral infection.
Tlr7 drives sex- and tissue-dependent effects in Sjögren's disease.
Punnanitinont A, Biswas S, Kasperek E, Osinski J, Zhu C, Miecznikowski J Front Cell Dev Biol. 2024; 12:1434269.
PMID: 39310226 PMC: 11413591. DOI: 10.3389/fcell.2024.1434269.
Pietraforte I, Butera A, Gaddini L, Mennella A, Palazzo R, Campanile D Int J Mol Sci. 2023; 24(1).
PMID: 36614095 PMC: 9820649. DOI: 10.3390/ijms24010653.
Rossmann L, Bagola K, Stephen T, Gerards A, Walber B, Ullrich A Proc Natl Acad Sci U S A. 2021; 118(39).
PMID: 34561306 PMC: 8488681. DOI: 10.1073/pnas.2103651118.
Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets.
Cecchi I, Radin M, Rodriguez-Carrio J, Tambralli A, Knight J, Sciascia S Expert Rev Clin Immunol. 2021; 17(4):395-406.
PMID: 33686921 PMC: 10183148. DOI: 10.1080/1744666X.2021.1901581.
Wampler Muskardin T, Fan W, Jin Z, Jensen M, Dorschner J, Ghodke-Puranik Y Front Immunol. 2020; 11:1384.
PMID: 32765497 PMC: 7378891. DOI: 10.3389/fimmu.2020.01384.